4.0 Article

The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era Prevention and Management

Journal

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
Volume 43, Issue 1, Pages 95-+

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2016.09.009

Keywords

Progressive multifocal leukoencephalopathy; Biologic therapy; Synthetic immunosuppressive therapy; Autoimmune rheumatic diseases; Systemic lupus erythematosus; Rituximab

Categories

Ask authors/readers for more resources

Progressive multifocal leukoencephalopathy (PML) is a rare, typically fatal, demyelinating central nervous system infection caused by reactivation of the John Cunningham virus that generally occurs in immunosuppressed patients. With an evolving understanding of a greater clinical heterogeneity of PML and significant implications for therapy, PML should be considered in the differential diagnosis of neurologic presentations of rheumatic diseases. Increased awareness of PML among rheumatologists is required, as earlier diagnosis and restoration of immune function may improve the otherwise grim prognosis associated with PML.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available